Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.

RSC Med Chem

Drug Design and Synthesis Laboratory, Department of Chemistry, Jamia Millia Islamia New Delhi 110025 India

Published: March 2022

Neurodegenerative disorders, , Alzheimer's or Parkinson's disease, involve progressive degeneration of the central nervous system, resulting in memory loss and cognitive impairment. The intensification of neurodegenerative research in recent years put some molecules into clinical trials, but still there is an urgent need to develop effective therapeutic molecules to combat these diseases. Chromone is a well-identified privileged structure for the design of well-diversified therapeutic molecules of potential pharmacological interest, particularly in the field of neurodegeneration. In this short review, we focused on the recent advancements and developments of chromones for neurodegenerative therapeutics. Different small molecules were reviewed as multi-target-directed ligands (MTDLs) with potential inhibition of AChE, BuChE, MAO-A, MAO-B, Aβ plaque formation and aggregation. Recently developed MTDLs emphasized that the chromone scaffold has the potential to develop new molecules for the treatment of neurodegenerative diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942243PMC
http://dx.doi.org/10.1039/d1md00394aDOI Listing

Publication Analysis

Top Keywords

small molecules
8
neurodegenerative therapeutics
8
therapeutic molecules
8
molecules
6
neurodegenerative
5
advancements chromone
4
chromone privileged
4
privileged scaffold
4
scaffold development
4
development small
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!